Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California.
Breast J. 2019 May;25(3):469-473. doi: 10.1111/tbj.13251. Epub 2019 Mar 29.
Patients with triple negative breast cancer were identified using the Surveillance, Epidemiology, and End Results database. Competing risks analysis was used to assess the cumulative incidence of breast cancer-specific mortality (BCSM). Multivariable Fine-Gray regression was used to identify predictors of BCSM. Women age 70+ (n = 4221) were less likely to receive chemotherapy and radiation treatment (P < 0.0001) and had higher BCSM compared to younger women (P < 0.0001). There were no differences in BCSM in patients who received adjuvant treatment (P = 0.10). Stage II patients derived the greatest relative and absolute benefit from adjuvant treatment. Age was not a significant predictor of BCSM.
使用监测、流行病学和最终结果数据库确定三阴性乳腺癌患者。使用竞争风险分析来评估乳腺癌特异性死亡率（BCSM）的累积发生率。多变量精细灰色回归用于确定 BCSM 的预测因素。年龄在 70 岁以上的女性（n=4221）接受化疗和放疗的可能性较低（P<0.0001），与年轻女性相比，BCSM 更高（P<0.0001）。接受辅助治疗的患者之间的 BCSM 无差异（P=0.10）。接受辅助治疗的 II 期患者获益最大。年龄不是 BCSM 的显著预测因素。
